Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sandoz Enbrel Copycat Next Biosimilar To Get Panel Treatment

Executive Summary

The FDA has elected to take Sandoz Inc.'s 351(k) application for its etanercept biosimilar, which is referenced on Amgen Inc.'s tumor necrosis factor blocker Enbrel, to an advisory committee to get its advice on whether to license the product. It's only the third biosimilar to get the expert panel treatment.

You may also be interested in...

Celltrion/Pfizer Inflectra Second US Biosimilar; Many Firsts

Move over Zarxio. There's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a while before patients have access to the new drug, since Celltrion Inc. and Pfizer Inc. said they won't put it on the market until after June 29.

Lawsuit: Sandoz Copycat Piggybacks Enbrel, Ducks Duties

For the second time, Novartis AG unit Sandoz Inc. is trying to "reap the commercial benefits" provided to biosimilar manufacturers under the Biologics Price Competition and Innovation Act (BPCIA), while seeking to avoid the obligations Congress established under the 2010 law "to protect innovators," Amgen Inc. and Roche AG charged in new court documents.

Panel Favors Celltrion Biosimilar; Skeptical On Cost Savings

With the favorable backing by an FDA advisory panel on Feb. 9, which followed a positive review by regulators, Celltrion Inc. and its partner Hospira Inc., a unit of Pfizer Inc., are well on their way of putting the first biosimilar of a monoclonal antibody on the US market.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts